Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/1999

01-08-1999 | ORIGINAL ARTICLE

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma

Authors: Tony S. K. Mok, Thomas W. T. Leung, Shou-Dong Lee, Yee Chao, Anthony T. C. Chan, Andrew Huang, Mei-Ching Lui, Winnie Yeo, Karen Chak, Amanda Johnston, Philip Johnson

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1999

Login to get access
Metadata
Title
A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma
Authors
Tony S. K. Mok
Thomas W. T. Leung
Shou-Dong Lee
Yee Chao
Anthony T. C. Chan
Andrew Huang
Mei-Ching Lui
Winnie Yeo
Karen Chak
Amanda Johnston
Philip Johnson
Publication date
01-08-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050982

Other articles of this Issue 4/1999

Cancer Chemotherapy and Pharmacology 4/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine